Clinical investigation of an outbreak of alveolitis and asthma in a car engine manufacturing plant

W Robertson, A S Robertson, C B S G Burge, V C Moore, M S Jaakkola, P A Dawkins, M Burd, R Rawbone, I Gardner, M Kinoult, B Crook, G S Evans, J Harris-Roberts, S Rice, P S Burge

Background: Exposure to metal working fluid (MWF) has been associated with outbreaks of extrinsic allergic alveolitis (EAA) in the USA, with bacterial contamination of MWF being a possible cause, but is uncommon in the UK. Twelve workers developed EAA in a car engine manufacturing plant in the UK, presenting clinically between December 2003 and May 2004. This paper reports the subsequent epidemiological investigation of the whole workforce. The study had three aims: (1) to measure the extent of the outbreak by identifying other workers who may have developed EAA or other work-related respiratory diseases; (2) to provide case detection so that those affected could be treated; and (3) to provide epidemiological data to identify the cause of the outbreak.

Methods: The outbreak was investigated in a three-phase cross-sectional survey of the workforce. In phase I a respiratory screening questionnaire was completed by 808/836 workers (96.7%) in May 2004. In phase II 481 employees with at least one respiratory symptom on screening and 50 asymptomatic controls were invited for investigation at the factory in June 2004. This included a questionnaire, spirometry and clinical opinion. 454/481 (94.4%) responded and 48/50 (96%) controls. Workers were identified who needed further investigation and serial measurements of peak expiratory flow (PEF). In phase III 162 employees were seen at the Birmingham Occupational Lung Disease clinic. 198 employees returned PEF records, including 141 of the 162 who attended for clinical investigation. Case definitions for diagnoses were agreed.

Results: 87 workers (10.4% of the workforce) met case definitions for occupational lung disease, comprising EAA (n = 19), occupational asthma (n = 74) and humidifier fever (n = 7). 12 workers had more than one diagnosis. The peak onset of work-related breathlessness was Spring 2003. The proportion of workers affected was higher for those using MWF from a large sump (27.3%) than for those working all over the manufacturing area (7.9%) (OR = 4.39, p < 0.001). Two workers had positive specific provocation tests to the used but not the unused MWF solution.

Conclusions: Extensive investigation of the outbreak of EAA detected a large number of affected workers, not only with EAA but also occupational asthma. This is the largest reported outbreak in Europe. Mist from used MWF is the likely cause. In workplaces using MWF there is a need to carry out risk assessments, to monitor and maintain fluid quality, to control mist and to carry out respiratory health surveillance.

Metal working fluids (MWF) have been recognised as causing work-related respiratory problems since the 1950s. Initial reports of respiratory effects due to the inhalation of oil mists were limited to lipoid pneumonia.1–3 Case reports of occupational asthma (OA) due to both clean and used MWF have been recorded.4–5 Subsequent surveys of workers exposed to MWF have found respiratory symptoms,6–9 often with associated bronchial hyper-responsiveness,7 9 cross-shift changes in lung function10–12 or reduced lung function.13 Many of these surveys have been done in the automotive industries.

The first cases of alveolitis due to MWF were reported in the mid 1990s by Bernstein et al in the USA who described six cases of hypersensitivity pneumonitis (extrinsic allergic alveolitis, EAA).14 Precipitating antibodies were found to a number of microbial isolates, the most common being Pseudomonas fluorescens. Further outbreaks in the USA have been reported,15–17 several in the automotive industry.18–20 Bacterial (particularly mycobacteria) or fungal contamination of MWF are thought to be the causes, but no specific agent has fulfilled the criteria for a specific cause.16–17 MWF has been an uncommon cause of EAA in the UK with only one case being reported to SWORD, the UK national voluntary notification scheme, from 1995 to 2002. Twelve employees from a car engine manufacturing plant in England who presented to us between December 2003 and May 2004 were diagnosed as having EAA. Dawkins et al have presented the findings from this case series of 12 workers, which showed heterogeneous clinical, radiological and pathological findings, but all met the case definition for EAA.18 The factory machined engine parts from aluminium alloys or cast iron and assembled car engines. The machining process used MWF (oil water emulsions with chemical additives including biocides). During use the MWF became contaminated by lubricating and hydraulic oil (tramp oil). Some machines had their own MWF sumps, but most used one of four common sumps, the largest with a capacity of >200 000 litres. Machined parts were washed with a mixture of water and detergent which was recirculated. Some washers produced inhalable aerosols.

In May 2004 we carried out an epidemiological investigation of the whole workforce which had three aims:

1. To measure the extent of the outbreak by identifying other workers who may have developed EAA or other work-related respiratory diseases.

Abbreviations: EAA, extrinsic allergic alveolitis; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HF, humidifier fever; MWF, metal working fluid; OA, occupational asthma; PEF, peak expiratory flow

See end of article for authors’ affiliations

Correspondence to: W Robertson, Lecturer in Public Health, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; W.Robertson@warwick.ac.uk

Received 25 September 2006
Accepted 6 April 2007
Published Online First 15 May 2007


www.thoraxjnl.com
employees who declared no symptoms on the respiratory screening questionnaire (11 questions on respiratory and nasal symptoms) was distributed to the 836 employees in May 2004. Workers were asked to report symptoms present in the previous 18 months. Non-responders were contacted twice more.

Phase II: Factory-based assessment

In June 2004 those workers with one or more respiratory symptoms and/or weight loss on the screening questionnaire were invited for further assessment. A control group of 50 asymptomatic workers was selected randomly from the 180 employees who declared no symptoms on the respiratory screening questionnaire. The selection of the controls was done with a random number table using the last three digits of their payroll number.

The assessment consisted of:

**Questionnaire**

A detailed self-completed questionnaire asked about demographic information, job history and clinical information (available on www.occupationalasthma.com/resources/outbreak_respiratory_survey.doc). The questionnaire inquired whether symptoms were “better”, the “same” or “worse” on “days away from work” and “holidays”. Symptoms were classified as work-related if they improved on days off or on holiday. The month and year of first onset of each symptom was recorded.

**Spirometry**

Spirometry was measured on a wedge bellows spirometer (Vitalograph) according to ATS/ERS standards using ECCS predicted values.

**Clinical opinion**

Participants were seen by an experienced occupational respiratory physician; those with possible OA were asked to record serial measurements of peak expiratory flow (PEF), with subsequent clinical investigation depending on the result. Those with possible alveolitis or humidifier fever (HF) were offered full clinical investigation (phase III).

**Phlebotomy**

20 ml blood was taken into two plain bottles with the serum frozen for later analysis for precipitins at the Health and Safety Laboratory (HSL), Sheffield, UK. The results are reported separately by the HSL.

Phase III: Full clinical assessment

**Peak flow records**

Standard instructions for PEF records included 2-hourly measurements from waking to bedtime on days at work and days away from work for a total of 4 weeks. Records were analysed using Oasys-2 computing program which plots and analyses serial measurements of PEF for occupational effect. Oasys-2 works by discriminant analysis, scoring “complexes” that are comprised of a work-rest-work pattern or a rest-work-rest pattern. Validation studies show that Oasys-2 has a sensitivity of 75% and a specificity of 94% for detecting OA.

An Oasys score of \( \geq 2.67 \) and/or a mean day interpreted difference between work and rest days of \( \geq 16 \text{ l/min} \) were defined as showing OA.

**Clinical investigation**

Workers selected in the previous phase were seen between November 2004 and March 2005 by two occupational respiratory physicians. Investigations included lung function tests, including transfer factor (single breath Jaeger Masterscreen system 2), chest radiograph and methacholine challenge (Yan method) for bronchial hyper-reactivity. Skin prick tests were performed for common environmental allergens with saline negative control, histamine positive control plus allergens – house dust, house dust mite, feathers, horse hair, cat dander, dog dander, mixed grasses, mixed tree pollens, plantain pollen, egg, milk, fish, wheat pollen, Cladosporium, Alternaria alternaria, Aspergillus fumigatus, Penicillium sp and Merulius lacrymans. Atopy was defined as at least one positive weal (\( \geq 3 \text{ mm above saline control} \)) to a common inhalable allergen. Lung volumes (helium dilution), high-resolution CT (HRCT) scans and bronchoscopy were performed if indicated. A clinical diagnosis was made on the results of investigations and history.

---

**Table 1**: Case definitions for work-related respiratory disease

<table>
<thead>
<tr>
<th>Disease</th>
<th>Criteria for case definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extrinsic allergic alveolitis (at least 4 of the 7 criteria must be met)</td>
<td>Onset of disease after December 2002 and: (1) physician diagnosis of EAA (probable or definite); (2) onset of at least two pulmonary symptoms (cough, wheeze, chest tightness, shortness of breath) and one systemic symptom (fever, weight loss); (3) a history of symptoms improving regularly on days away from work and deteriorating on return to work; (4) Restrictive pattern on spirometry: FVC &lt;80% predicted and FEV1/FVC &gt;70%; (5) pulmonary carbon monoxide transfer factor &lt;80% predicted; (6) chest radiograph or CT scan showing interstitial, reticulonodular or mosaic pattern; (7) biopsy evidence of non-caseating granulomas and/or lymphocytosis on bronchoalveolar lavage</td>
</tr>
<tr>
<td>Occupational asthma</td>
<td>Diagnostic peak expiratory flow record in 2003–5 (ie, OASYS score ≥2.67 and/or a mean day interpreted difference between work and rest days of ≥16 l/min)</td>
</tr>
<tr>
<td>Humidifier fever</td>
<td>Onset of disease after December 2002 and a physician diagnosis based on: Recurrent symptoms of a flu-like illness worst on first day of exposure after a break; No weight loss or radiological infiltrates; No long-term restrictive lung disease</td>
</tr>
</tbody>
</table>

EAA, extrinsic allergic alveolitis; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
Case definitions
Case definitions for work-related respiratory diseases were agreed (table 1) and applied to workers that had undergone further clinical investigations. Case definitions for EAA were adapted from Fox et al. OA required a diagnostic PEF record and HF was based on history (table 1). We defined January 2003 as the onset date for the outbreak based on the presentation of the 12 index cases of EAA.

Specific challenge tests
Two individuals, one with a pre-test diagnosis of EAA and one with OA and resolved HF, had occupational-type bronchial provocation testing 6 months after removal from exposure. Challenges to unused MWF used at the factory (a mixture of two products and water containing a number of chemicals including tolytriazole, ethanolamines, tall oil and boric acid) and used MWF taken from the largest common sump were performed on separate days. Initially, exposures were by a Pari Pot nebuliser with the aerosol directed generally into the challenge chamber for sequential periods of 10, 20 then 40 min (total exposure 70 min). Rest breaks occurred between challenges and any significant response would have terminated the challenge. Further challenges were made with the aerosol inhaled directly from the nebuliser using a mouthpiece for up to 17 min (2, 5 and 10 min with breaks). Spirometric parameters were measured pre-challenge and regularly for at least 11 h post-challenge. A fall in forced expiratory volume in 1 s (FEV1) of >15% from baseline was taken as a positive test.

Environmental investigation
Over the period of the outbreak, area and personal measurements of MWF in air were conducted using Health and Safety Executive (HSE) standard methodology, estimating total aerosol by extrapolating from the boron content of MWF. Personal sampling was done over a 4–5-h period. Common sumps were monitored for pH, concentration, tramp oil, bacteria and fungi. Smaller sumps were monitored for concentration and pH. From November 2003, sump samples were analysed for bacteria and fungi.

Ethical approval
Ethical approval was not obtained as this report is the result of surveillance and the investigation of surveillance failures required by a legally binding improvement notice from the Health and Safety Executive. The surveillance was approved by both worker and management representatives.

Analysis of data
The onset (month and year) of work-related breathlessness reported in the phase II questionnaire was plotted and related to the concentration of tramp oil in MWF. Gender, ethnicity, smoking and use of MWF were then compared for the affected and non-affected populations using a χ² test (with Yates correction).
The prevalence of work-related respiratory disease (EAA, OA and HF) was calculated for the 57 operational codes using the number working in each operational code as the denominator. Fisher’s exact test was used to compare the proportion with disease in a specific work location with the proportion of disease in the rest of the workforce. Each code was also assigned to one of the following five groups: (1) machining using MWF from a single or local sump; (2) machining using MWF directly (predominantly assembly jobs); (4) working all over the plant in the manufacturing area; and (5) working outside the main plant or in the office block.

Logistic regression was used to see if the occurrence of disease differed across these five location groups and an odds ratio was obtained using the fourth group (working all over the plant in the manufacturing area; and (5) working outside the main plant or in the office block.

The detailed questionnaire showed that 146 employees had at least grade 1 MRC breathlessness, which was better on days away from work and/or on holiday (“work-related”) (table 3). Of these, 54/127 who gave a year when they first developed breathlessness had an onset in 2003 or later. Seventy workers of these, 54/127 who gave a year when they first developed breathlessness had an onset in 2003 or later. Seventy workers (18%) had eye or nasal symptoms only and 180 (22%) were asymptomatic.

**Phase II: Factory-based assessment**
Four hundred and fifty-four (94.4%) of the 481 workers with at least one respiratory symptom on the screening questionnaire and 48/50 (96%) asymptomatic “controls” attended phase II. Table 2 shows their demographic characteristics. Compared with asymptomatic controls, those with respiratory symptoms had lower lung function, more worked in manufacturing and more smoked.

**Phase III: Full clinical assessment**
One hundred and seventy-three employees were identified for further investigation. Based on clinical opinion, 102 workers were diagnosed with probable or definite occupational lung disease including 24 with EAA, 88 with OA and 7 with HF (some with more than one diagnosis).
one diagnosis). Additionally, 15 workers were diagnosed with occupational bronchitis (defined by cough productive of sputum which was better away from exposure). There were also single cases of bronchopulmonary aspergillosis (diagnosed immunologically), lipoid pneumonitis and Langerhans’ cell histiocytosis (both diagnosed from histology).

Phase III: Numbers meeting the case definitions
Nineteen workers met the case definition for EAA (at least four of the seven criteria; table 4). Sixteen of these had the onset of symptoms after January 2003 (table 4). Seventy-four of the 198 employees who returned PEF records had a recording which met the case definition for OA (table 4). Half of these had first

Table 3  Self-reported work-related respiratory symptoms at the factory assessment (phase II)

<table>
<thead>
<tr>
<th>Respiratory symptoms on screening questionnaire (n = 454)*</th>
<th>Controls: asymptomatic on screening questionnaire (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Work-related  n (%)</td>
<td>Not work-related  n (%)</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>MRC Breathlessness</strong></td>
<td></td>
</tr>
<tr>
<td>MRC1: Troubled by shortness of breath when hurrying on level ground or walking up a slight hill</td>
<td>146 (17.5%)</td>
</tr>
<tr>
<td>MRC2: Short of breath walking with other people of own age and sex on level ground</td>
<td>89 (10.6%)</td>
</tr>
<tr>
<td>MRC3: Had to stop for breath when walking at own pace on level ground</td>
<td>41 (4.9%)</td>
</tr>
<tr>
<td>MRC4: Short of breath washing or dressing</td>
<td>16 (1.9%)</td>
</tr>
<tr>
<td><strong>MRC Chronic Bronchitis</strong></td>
<td></td>
</tr>
<tr>
<td>MRC chronic bronchitis: sputum production for 3 months each year for 2 years or more</td>
<td>78 (9.3%)</td>
</tr>
<tr>
<td><strong>Asthma type symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>In last 12 months has your chest ever felt tight or your breathing become difficult?</td>
<td>156 (18.6%)</td>
</tr>
<tr>
<td>In the past 12 months have you had wheezing or whistling in your chest?</td>
<td>122 (14.6%)</td>
</tr>
<tr>
<td><strong>Humidifier fever type symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>In the past 12 months have you suffered recurrent flu-like symptoms on five or more occasions? (Work-relatedness was defined as symptoms at the beginning of the working week and/or being more frequent/severe on returning to work after a weekend or holiday)</td>
<td>18 (2.1%)</td>
</tr>
</tbody>
</table>

*Note that the total workforce of 836 used as denominator.
onset of asthma-type symptoms since January 2003. Eight of the 74 also met the EAA case definition. Taking into account the overlap of disease, 87 employees (10.4% of the workforce) met case definitions for one or more of EAA, OA and HF (fig 3). Hereafter the analysis will refer to these 87 workers.

Unexpectedly, a “control” who was asymptomatic on the screening questionnaire was diagnosed as having OA, supported by a diagnostic PEF record (fig 1). During clinical investigation he denied many symptoms. His spirometric parameters were abnormal (FEV₁ 68%, FVC 74% predicted). Workers who met the case definition for EAA and OA were compared with the asymptomatic controls (table 2). Those with EAA had restrictive disease with the lowest FEV₁ and FVC, those with OA had obstructive spirometry (on average), and the controls had values above predicted as would be expected for a healthy worker population. There was no difference in the smoking history, demographic characteristics or the length of employment in the three groups. However, almost all of those with OA (97%) and all with EAA (100%) worked in the manufacturing areas, significantly higher than the proportion in the control group (61%). Also, a higher proportion of those with EAA and OA had worked directly with MWF compared with the controls.

Skin tests for atopic status were performed on 13/19 workers with EAA and 61/66 workers with OA; 3/13 (23%) with EAA and 33/61 (54%) with OA were atopic, showing the risk of OA to be associated with atopy.

**Work location of the 87 workers with work-related respiratory disease (phase III)**

The 87 workers with disease were distributed across 22 work locations in the factory (fig 4), with no workers with disease in 35 other work locations (as defined by their operational codes). Geographically, the cases of disease were clustered at the northern end of the factory. The work location with the highest number of cases was an engine assembly area (Assembly 1), but this also had the largest number of employees. As the numbers working in each location varies, the prevalence of disease is shown in fig 5. Four work locations all involved in machining (Machining 1, 2, 3 and 5) had a significantly higher rate of disease compared with the rest of the factory (fig 5). These four work locations were all in the northern half of the factory served directly by the largest common MWF sump (200 000 litres) or directly adjacent to it. A map of the factory showing the prevalence of disease for the work locations together with the location of the four main sumps and two washers shown to generate mist (Map 1) is given in the online supplement available at http://thorax.bmj.com/supplemental.

Table 5 shows the distribution of cases across the five work location groups (see Map 2 in the online supplement available at http://thorax.bmj.com/supplemental for the location of these five areas within the factory). Working in machining using MWF from the largest common sump was associated with an increased risk of having disease of more than four times (27.3%) compared with workers who worked all over the manufacturing area (7.9%) (odds ratio (OR) 4.39, 95% CI 2.00 to 9.60). Further analysis by type of disease showed that machining using MWF from the large sump significantly increased the odds of developing OA (OR 4.36, 95% CI 1.69 to 11.24); for EAA the OR was increased but this was not statistically significant (OR 2.62, 95% CI 0.73 to 9.38).

### Challenge results

Of the two workers challenged, the worker with alveolitis had a late reaction to used MWF with a 14.6% fall in FEV₁ following
indirect exposure and a 22% fall after direct exposure, with
<1% change following unused MWF exposure. He had normal
methacholine reactivity throughout. The worker with OA had a
borderline reaction to the indirect exposure (immediate 13.7%,
late 11.2% with a lower FEV₁ the following morning) and a
significant dual asthmatic reaction with direct exposure
(immediate 21.7%, late 13%; fig 6). His methacholine reactivity
deteriorated from 2400 µg (normal >2000 µg) before the
challenge to 300 µg the day after the positive challenge.

Environmental results
Results of air monitoring between May 2002 and October 2003
showed that concentrations of MWF in air were generally
below the then HSE guidance value of 1 mg/m³. In October
2003 the levels of mineral oil mist in air were between 1 and
4 mg/m³ with an average concentration of just above 1 mg/m³,
also generally below the exposure guidance value of 3 mg/m³.  
Personal samples of mineral oil mist taken at the same time
indicated exposures of 1–1.7 mg/m³, with an average exposure
of 1.3 mg/m³.

Samples of MWF taken from the largest common sump in
August 2004 showed no bacterial, mycobacterial or fungal
growth, with no increased endotoxin levels. DNA extraction
identified *Acinetobacter* spp and *Ochrobacter anthropi*, but no
*Mycobacterium* spp. *Acinetobacter* spp and *Ochrobacter anthropi*
were grown from washing machines.

Factory records showed a steep rise in tramp oil in the MWF
in the large communal sump around April 2003, just after the
hydraulic oil used in machines was changed (fig 2). A
complicating factor was the highest number of workers
reported onset of breathlessness in March 2003, just before
the tramp oil increased.

DISCUSSION
The current investigation of employees in a car manufacturing
plant in the UK detected 19 workers with EAA according to a
strict case definition. During the investigation we also
uncovered a large unknown outbreak of OA, with 74 workers
diagnosed on the basis of serial peak flow records which are
both reasonably sensitive and very specific for identifying
patients with OA. A total of 87 workers met case
definitions for OA and/or EAA and/or HF, an overall prevalence
in the workforce of 10%. Half of the workers with OA had
symptoms before 2003 (the date for new onset was defined as
January 2003 or later based on the 12 index cases of EAA),
suggesting that the outbreak of OA may have begun earlier
than the outbreak of EAA.

Figure 4 Work location of 87 workers with work-related respiratory disease. EAA, extrinsic allergic alveolitis; OA, occupational asthma; HF, humidifier fever.

Figure 5 Percentage (with 95% confidence intervals) of workers with work-related respiratory disease by work location;
*p<0.05, **p<0.01 work location higher than rest of workforce.
We also identified workers with HF and work-related chronic bronchitis, as well as single cases of histologically confirmed lipoid pneumonitis and Langerhans’ cell histiocytosis and immunologically confirmed bronchopulmonary aspergillosis. The variety of different presentations of work-related respiratory disease related to exposure to MWF in the current study is consistent with other outbreaks of EAA in the USA. Zacharisen et al reported cases of EAA, asthma and bronchitis in a car engine manufacturing plant. Hodgson et al found that many workers with EAA also had asthma, and there was at least one case of usual interstitial pneumonia and a case of sarcoidosis at the plant which produced titanium and steel parts for the aerospace industry. Similarly, in the present investigation 8 of the 19 workers who met the case definition for EAA also had peak flow variability consistent with the case definition for OA. EAA can produce findings of airways obstruction on spirometry, possibly due to associated bronchiolitis. It is conceivable that such airways obstruction would also show a work-related pattern.

Before further interpreting the results, it is important that the methodological limitations are discussed. First, with 87 cases of work-related respiratory disease observed at the factory, the size of the control group (n = 50) may seem rather low. The number of controls had to be decided at the start of the investigation as the data collection had to happen for all at the same time, before the remedial action at the factory commenced. At that time the number of known (index) cases of EAA was only 12 and we were unaware of any cases of OA, so the sample size of 50 controls was thought to be reasonable. Second, a lower proportion of the control group worked in the manufacturing area compared with cases of OA and EAA and, as a consequence, they had less potential to be exposed to MWF. This was because the control population was selected from the asymptomatic workers identified from the screening questionnaire. The selection bias in the control group probably does not affect the results presented in this paper, as the focus of the paper is more about the epidemiology of those with respiratory illness. The results from this control group does reaffirm that working in the manufacturing area is associated with an increased risk of disease.

Another methodological issue is that the date of onset of symptoms was established retrospectively from the

<table>
<thead>
<tr>
<th>Work location</th>
<th>Total population (n)</th>
<th>Met case definition for EAA, OA and/or HF</th>
<th>OR (95% CI) vs “works all over”</th>
<th>Met case definition for EAA (8 also had OA)</th>
<th>OR (95% CI) vs “works all over”</th>
<th>Met case definition for OA</th>
<th>OR (95% CI) vs “works all over”</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Machining using large MWF sump</td>
<td>66</td>
<td>18 (27.3%)</td>
<td>4.39 (2.00 to 9.60) p&lt;0.001</td>
<td>5 (7.6%)</td>
<td>2.62 (0.73 to 9.38) p=0.138</td>
<td>12 (18.2%)</td>
<td>4.36 (1.69 to 11.24) p=0.002</td>
</tr>
<tr>
<td>(2) Machining using single/local MWF sumps</td>
<td>150</td>
<td>19 (12.7%)</td>
<td>1.70 (0.81 to 3.57) p=0.164</td>
<td>2 (1.3%)</td>
<td>0.43 (0.08 to 2.26) p=0.321</td>
<td>16 (10.7%)</td>
<td>2.34 (0.97 to 5.65) p=0.058</td>
</tr>
<tr>
<td>(3) Assembly and other manufacturing</td>
<td>320</td>
<td>36 (11.3%)</td>
<td>1.48 (0.76 to 2.88) p=0.246</td>
<td>7 (2.2%)</td>
<td>0.72 (0.22 to 2.29) p=0.573</td>
<td>29 (9.1%)</td>
<td>1.96 (0.87 to 4.38) p=0.103</td>
</tr>
<tr>
<td>(4) Works all over plant</td>
<td>165</td>
<td>13 (7.9%)</td>
<td>1</td>
<td>5 (3.0%)</td>
<td>1</td>
<td>8 (4.8%)</td>
<td>1</td>
</tr>
<tr>
<td>(5) Outside/office building</td>
<td>135</td>
<td>1 (0.7%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (0.7%)</td>
<td>1 (0.7%)</td>
<td>1 (0.7%)</td>
</tr>
<tr>
<td>Total</td>
<td>836</td>
<td>87 (10.4%)</td>
<td>19 (2.3%)</td>
<td>66 (7.9%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Denominators are total population in each work location.

Figure 6 Bronchial provocation challenge test with unused and used metal working fluid on a worker with occupational asthma. FEV₁, forced expiratory volume in 1 s.
self-completed questionnaire more than 15 months after the onset of the outbreak. Only 70 of the 146 workers with work-related breathlessness were able to identify the month of onset. There were no contemporary surveillance data. With these caveats, there appears to be a peak incidence in March 2003, just before a new hydraulic oil for metal working machines was introduced in April 2003. The new hydraulic oil was more soluble in the MWF, increasing the concentration of tramp oil in the MWF. However, as the change in hydraulic oil occurred after the start of the outbreak, there is no clear evidence that this change is significant. The outbreak also coincided with reports of increased misting in the factory during the winter period when the roof louvers were closed.

Although factory records historically showed little bacterial growth, our own microbiological investigations in the factory found Acinetobacter spp and Ochrobactrum anthropi cultured from the washer fluid. DNA from these bacteria was also identified in the MWF from the largest sump, although there was no culture. No Mycobacterium spp were identified either from culture or from DNA extraction. The Health and Safety Laboratory has carried out a parallel immunological investigation of the workers at the factory in the current investigation which is reported in detail elsewhere. MWF from the largest common sump at the time of the outbreak and extracts from cultures of Acinetobacter spp, Ochrobactrum anthropi and Mycobacterium spp were used to look for the presence of precipitating antibodies. In those with EAA, 5% had precipitating antibodies to OA and 5% of asymptomatic workers (controls). This is unlike other outbreaks of alveolitis where precipitating antibodies were found in only 10% of those with OA and 5% of asymptomatic workers (controls). This is unlike other outbreaks of alveolitis where precipitating antibodies are commonly found in asymptomatic subjects. No workers tested positive for precipitating antibodies to Metalworking fluid guidance value of 1 mg/m³ and the mineral oil in air contamination of MWF—and in particular Acinetobacter species. These results indicate that bacterial contamination of MWF—and in particular Acinetobacter species—had at least a contributory role in the cases of EAA.

The overall levels of mist from both MWF and mineral oil sources were unremarkable, with most levels below the then MWF guidance value of 1 mg/m³ and the mineral oil in air guidance value of 3 mg/m³. The Health and Safety Executive (the UK regulatory body for health and safety) has since withdrawn these guidance values.

The highest number of cases was in one of the assembly areas which was about 30 metres from the common sump, suggesting that the causative aerosol was relatively widespread. Two washers vented inside the factory and were also in the northern end of the factory. Given the wide distribution of disease in the factory, the most likely cause was an aerosol from either the metalworking and/or washing operations, although no material within this mist has been confirmed as a specific causal agent.

The potential of other exposure factors as a cause of this outbreak was considered. Metal particles can produce an intrapulmonary inflammatory response and some specific metals are well recognised causes of OA. These are mainly platinum salts, chrome, cobalt and, to a lesser extent, zinc and nickel. At the factory the engines were made of aluminium alloy. There was no platinum, chrome or nickel. There was one machine where hard metal valve rings were machined. Cobalt levels in the MWF were insignificant and levels were checked in the urine of workers and were normal. There is some doubt as to whether aluminium alone can cause OA. The main work on aluminium and asthma comes from smelters where aluminium sodium fluoride is a possible cause. It has never been described in those working with cold aluminium. There were no sources of nitrogen oxides (no heating of the metal). However, the potential for other chemical constituents to be either causal or to have had a co-effect cannot be discounted. The Health and Safety Executive has compiled a list of the constituents and contaminants of the MWF and wash fluids at the factory which were considered in the original investigation as possible causes of either EAA or OA (see online supplement available at http://thorax.bmj.com/supplemental).

During bronchial challenge tests two workers (one with OA and one with EAA) confirmed reactions to the used MWF taken from the common sump but not the clean MWF. The used MWF will contain material from the aluminium alloy castings, microbial contamination and added biocides, pH adjusters, etc. The lack of reaction to the unused MWF indicates that the chemical constituents alone were unlikely to have caused the disease.

As a consequence of this outbreak UK policy has changed, firstly for the users of MWF and secondly for those affected by EAA. First, the “lessons learned” from this outbreak have been published by the Health and Safety Executive on their website (this is available in the online Appendix at http://thorax.bmj.com/supplemental), detailing the practical implications for other users of MWF. This outbreak showed that adhering to the guidance standards of oil mist did not prevent respiratory disease and has led to their withdrawal by the Health and Safety Executive. Furthermore, the Health and Safety Executive has since issued new guidance on safe working practices that includes a requirement for respiratory surveillance. They have subsequently carried out a national survey of large users of MWF in 2005/6 to identify the extent to which guidance was being followed, with many deficiencies noted.

Second, there is an anomaly in that OA due to oil mists is compensatable in the UK through a no-fault compensation system from the UK Government’s Department for Work and Pensions, but EAA due to anything other than fungal or avian antigens is not. OA is known to adversely affect income and clinical outcome, whereas the impact of EAA is likely to be at least as important. In July 2006 the Industrial Injuries Advisory Council (who advise the Department of Work and Pensions of the list of prescribed diseases for compensation) recommended that the occupational coverage for EAA should include exposure to mists from MWF. This has now had ministerial approval and “work involving exposure to MWF” as a cause of EAA was added to the list of prescribed diseases on 6 April 2007.

Finally, it is of interest to note what happened after the outbreak at the factory. After the assessment at the factory in June 2004 a series of control measures was introduced including:

- replacing MWF in the large common sumps;
- cleaning machines with individual sumps (both metalworking and washing) which were heavily contaminated with bacteria and then refilling them with fresh fluid;
- treating other less contaminated sumps with biocide;
- supplying employees with respiratory protection with powered respirators for those with known disease; and
- instituting respiratory surveillance for all employees.

Continued surveillance using occupational PEF records was carried out for those with OA, and a few had persistent OA despite the extensive control measures. The factory went into administration in April 2005. The machinery was subsequently bought by Nanjing Automobile (Group) Corporation and removed to China. Nanjing has been warned about the risks.

CONCLUSIONS

This investigation of an outbreak of EAA in a car manufacturing plant detected a large number of affected workers—not
only EAA but also OA—and is the largest reported outbreak in Europe. Mist from used MWF is the likely cause although oil mist levels were generally below guidance values, emphasising that it was time to reconsider the standards and issue new guidelines. Our study suggests that, in workplaces using MWF and wash fluids, there is a need to carry out risk assessments, ensure that fluid quality is monitored and maintained, improve the control of mist and carry out respiratory health surveillance on exposed workers.

ACKNOWLEDGEMENTS
The authors acknowledge and thank Professor Tony Pickering, Geraldine Bale, Dr Clara Dawkins, Dr Angela Fletcher and Dr Fred Bio for their invaluable support with the factory based assessment, Rowan Campbell for data entry, Dr Richard Southam and the factory management for their administrative support.

Additional information is given in the online supplement available at http://thorax.bmj.com/

Authors’ affiliations
W Robertson, Department of Public Health, Health Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, UK
A S Robertson, C B S G Burge, V C Moore, P S Burge, Occupational Lung Disease Unit, Birmingham Heartlands Hospital, Birmingham, UK
M S Jaakkola, Institute of Occupational and Environmental Medicine, University of Birmingham, Birmingham, UK
P A Dawkins, Department of Medicine, University of Birmingham, Birmingham, UK
M Burd, R Rawbone, I Gardner, M Kinouy, Health and Safety Executive, Birmingham, UK
B Crook, G S Evans, J Harris-Roberts, S Rice, Health and Safety Laboratory, Buxton, UK

Data entry was funded by the company.

Competing interests: None declared.

REFERENCES
Clinical investigation of an outbreak of alveolitis and asthma in a car engine manufacturing plant

W Robertson, A S Robertson, C B S G Burge, V C Moore, M S Jaakkola, P A Dawkins, M Burd, R Rawbone, I Gardner, M Kinoult, B Crook, G S Evans, J Harris-Roberts, S Rice and P S Burge

Thorax 2007 62: 981-990 originally published online May 15, 2007
doi: 10.1136/thx.2006.072199

Updated information and services can be found at:
http://thorax.bmj.com/content/62/11/981

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2007/10/25/thx.2006.072199.DC1

References
This article cites 27 articles, 7 of which you can access for free at:
http://thorax.bmj.com/content/62/11/981#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Screening (epidemiology) (366)
- Screening (public health) (366)
- Airway biology (1100)
- Interstitial lung disease (559)
- Lung function (773)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/